| 1 |
35059243 | The forgotten type 2 diabetes mellitus medicine: rosiglitazone. | 2022 Jan |
2 |
| 2 |
35203272 | Potential Therapeutic Effects of PPAR Ligands in Glioblastoma. | 2022 Feb 10 |
1 |
| 3 |
35309069 | The Role of Peroxisome Proliferator-Activated Receptor Gamma and Atherosclerosis: Post-translational Modification and Selective Modulators. | 2022 |
2 |
| 4 |
35420373 | Update on Uric Acid and the Kidney. | 2022 May |
1 |
| 5 |
35498407 | Combination Therapy With Semaglutide and Dapagliflozin as an Effective Approach for the Management of Type A Insulin Resistance Syndrome: A Case Report. | 2022 |
1 |
| 6 |
31916505 | Virtual screening, molecular dynamics, density functional theory and quantitative structure activity relationship studies to design peroxisome proliferator-activated receptor-γ agonists as anti-diabetic drugs. | 2021 Feb |
2 |
| 7 |
33106148 | Efficacy and Cardiovascular Safety of Thiazolidinediones. | 2021 |
2 |
| 8 |
33670968 | Mechanistic Insights into Side Effects of Troglitazone and Rosiglitazone Using a Novel Inverse Molecular Docking Protocol. | 2021 Feb 28 |
1 |
| 9 |
33866775 | Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus. | 2021 May |
1 |
| 10 |
33927970 | Role of insulin receptor substance-1 modulating PI3K/Akt insulin signaling pathway in Alzheimer's disease. | 2021 Apr |
1 |
| 11 |
34127848 | PPAR control of metabolism and cardiovascular functions. | 2021 Dec |
1 |
| 12 |
34133753 | Thiazolidinediones (TZDs) enhance insulin secretory response via GPR40 and adenylate cyclase (AC). | 2021 Dec |
4 |
| 13 |
34221378 | Drug repurposing in autosomal dominant polycystic kidney disease: back to the future with pioglitazone. | 2021 Jul |
1 |
| 14 |
34407851 | Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis. | 2021 Aug 18 |
5 |
| 15 |
34417811 | Rosiglitazone Requires Hepatocyte PPARγ Expression to Promote Steatosis in Male Mice With Diet-Induced Obesity. | 2021 Nov 1 |
1 |
| 16 |
34563556 | Insulin resistance and insulin sensitizing agents. | 2021 Dec |
1 |
| 17 |
31449359 | Therapeutic approaches for latent autoimmune diabetes in adults: One size does not fit all. | 2020 Feb |
1 |
| 18 |
31969093 | Pharmacological Strategies for Insulin Sensitivity in Obesity and Cancer: Thiazolidinediones and Metformin. | 2020 |
4 |
| 19 |
32238842 | Clinical outcomes of basal insulin and oral antidiabetic agents as an add-on to dual therapy in patients with type 2 diabetes mellitus. | 2020 Apr 1 |
1 |
| 20 |
32344313 | Can pioglitazone be potentially useful therapeutically in treating patients with COVID-19? | 2020 Jul |
2 |
| 21 |
32363472 | Does glitazone treatment have a role on the prevention of Parkinson's disease in adult diabetic population? A systematic review. | 2020 Oct |
1 |
| 22 |
32532851 | DPP4i, thiazolidinediones, or insulin and risks of cancer in patients with type 2 diabetes mellitus on metformin-sulfonylurea dual therapy with inadequate control. | 2020 Jun |
2 |
| 23 |
32766764 | Peroxisome proliferator-activated receptor gamma expression along the male genital system and its role in male fertility. | 2020 Sep 1 |
1 |
| 24 |
30398029 | Trans-repression of NFκB pathway mediated by PPARγ improves vascular endothelium insulin resistance. | 2019 Jan |
2 |
| 25 |
30506494 | Differential Effects of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors on Insulin Resistance and β-Cell Function in Type 2 Diabetes Mellitus: A Propensity Score-Matched Analysis. | 2019 Feb |
1 |
| 26 |
31014100 | Insulin resistance: Impact on therapeutic developments in diabetes. | 2019 Mar |
2 |
| 27 |
31129998 | Understanding Contemporary Use of Thiazolidinediones. | 2019 Jun |
1 |
| 28 |
31131751 | PPARγ: Potential Therapeutic Target for Ailments Beyond Diabetes and its Natural Agonism. | 2019 |
2 |
| 29 |
31591015 | Design, synthesis, and evaluation of potent novel peroxisome proliferator-activated receptor γ indole partial agonists. | 2019 Nov 15 |
1 |
| 30 |
31776781 | Thiazolidinediones: the Forgotten Diabetes Medications. | 2019 Nov 27 |
3 |
| 31 |
28641522 | Advances on PPARγ Research in the Emerging Era of Precision Medicine. | 2018 |
3 |
| 32 |
29469167 | Higher mortality rate in patients with heart failure who are taking commonly prescribed antidiabetic medications and achieve recommended levels of glycaemic control. | 2018 Jul |
1 |
| 33 |
29581079 | Thiazolidinediones and Risk of Atrial Fibrillation Among Patients with Diabetes and Coronary Disease. | 2018 Jul |
2 |
| 34 |
29736714 | Discovery of Modulators of Adipocyte Physiology Using Fully Functionalized Fragments. | 2018 |
3 |
| 35 |
30062227 | Potentiation of Insulin Signaling Contributes to Heart Failure in Type 2 Diabetes: A Hypothesis Supported by Both Mechanistic Studies and Clinical Trials. | 2018 Jun |
2 |
| 36 |
30079233 | Re-highlighting the action of PPARγ in treating metabolic diseases. | 2018 |
1 |
| 37 |
30123711 | Indole and 2,4-Thiazolidinedione conjugates as potential anticancer modulators. | 2018 |
3 |
| 38 |
30278161 | New insights into molecular mechanisms of rosiglitazone in monotherapy or combination therapy against cancers. | 2018 Dec 25 |
2 |
| 39 |
30328521 | Pathogenesis of Lipid Disorders in Insulin Resistance: a Brief Review. | 2018 Oct 17 |
1 |
| 40 |
30413050 | Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once? | 2018 Nov 8 |
1 |
| 41 |
30429097 | PPARγ-sparing thiazolidinediones as insulin sensitizers. Design, synthesis and selection of compounds for clinical development. | 2018 Dec 1 |
1 |
| 42 |
28093996 | Challenges Related to Glycemic Control in Type 2 Diabetes Mellitus Patients. | 2017 |
1 |
| 43 |
28275367 | PPAR-γ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis. | 2017 |
4 |
| 44 |
28404813 | Cycling our way to fit fat. | 2017 Apr |
2 |
| 45 |
28589542 | Is insulin the preferred treatment for HbA1c >9%? | 2017 Sep |
1 |
| 46 |
28611274 | Meta-Analysis of Randomized Controlled Trials of Pharmacologic Agents in Non-alcoholic Steatohepatitis. | 2017 Jul-Aug |
1 |
| 47 |
28716729 | Study of new interactions of glitazone's stereoisomers and the endogenous ligand 15d-PGJ2 on six different PPAR gamma proteins. | 2017 Oct 15 |
3 |
| 48 |
29056962 | Chiglitazar Preferentially Regulates Gene Expression via Configuration-Restricted Binding and Phosphorylation Inhibition of PPARγ. | 2017 |
4 |
| 49 |
26381272 | Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies. | 2016 Feb |
1 |
| 50 |
26917795 | Pioglitazone therapy for HIV/HAART-associated lipodystrophy syndrome could increase subcutaneous fat mass in non-lipoatrophic but not in lipoatrophic regions. | 2016 Feb 25 |
1 |